Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Extensive rewiring of the EGFR network in colorectal cancer cells expressing transforming levels of KRASG13D

  • Kennedy, Susan A.
  • Kiel, Christina
  • Serrano Pubull, Luis, 1982-
  • Kolch, Walter
Protein-protein-interaction networks (PPINs) organize fundamental biological processes, but how oncogenic mutations impact these interactions and their functions at a network-level scale is poorly understood. Here, we analyze how a common oncogenic KRAS mutation (KRASG13D) affects PPIN structure and function of the Epidermal Growth Factor Receptor (EGFR) network in colorectal cancer (CRC) cells. Mapping >6000 PPIs shows that this network is extensively rewired in cells expressing transforming levels of KRASG13D (mtKRAS). The factors driving PPIN rewiring are multifactorial including changes in protein expression and phosphorylation. Mathematical modelling also suggests that the binding dynamics of low and high affinity KRAS interactors contribute to rewiring. PPIN rewiring substantially alters the composition of protein complexes, signal flow, transcriptional regulation, and cellular phenotype. These changes are validated by targeted and global experimental analysis. Importantly, genetic alterations in the most extensively rewired PPIN nodes occur frequently in CRC and are prognostic of poor patient outcomes., This work was supported by European Union FP7 Grant No. 278568 “PRIMES” and Science Foundation Ireland Investigator Program Grant 14/IA/2395 to W.K. B.K. is supported by SmartNanoTox (Grant no. 686098), NanoCommons (Grant no. 731032), O.R. by MSCA-IF-2016 SAMNets (Grant no. 750688). D.M. is supported by Science Foundation Ireland Career Development award 15-CDA-3495. I.J. is supported by the Canada Research Chair Program (CRC #225404), Krembil Foundation, Ontario Research Fund (GL2-01-030 and #34876), Natural Sciences Research Council (NSERC #203475), Canada Foundation for Innovation (CFI #225404, #30865), and IBM. O.S. is supported by ERC investigator Award ColonCan 311301 and CRUK. I.S. is supported by the Canadian Cancer Society Research Institute (#703889), Genome Canada via Ontario Genomics (#9427 & #9428), Ontario Research fund (ORF/ DIG-501411 & RE08-009), Consortium Québécois sur la Découverte du Médicament (CQDM Quantum Leap) & Brain Canada (Quantum Leap), and CQDM Explore and OCE (#23929). T.C. was supported by a Teagasc Walsh Fellowship
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A RAC-GEF network critical for early intestinal tumourigenesis

  • Pickering, Karen
  • Unal, E. Besray
  • Kiel, Christina
  • Serrano Pubull, Luis, 1982-
  • Sansom, Owen J.
RAC1 activity is critical for intestinal homeostasis, and is required for hyperproliferation driven by loss of the tumour suppressor gene Apc in the murine intestine. To avoid the impact of direct targeting upon homeostasis, we reasoned that indirect targeting of RAC1 via RAC-GEFs might be effective. Transcriptional profiling of Apc deficient intestinal tissue identified Vav3 and Tiam1 as key targets. Deletion of these indicated that while TIAM1 deficiency could suppress Apc-driven hyperproliferation, it had no impact upon tumourigenesis, while VAV3 deficiency had no effect. Intriguingly, deletion of either gene resulted in upregulation of Vav2, with subsequent targeting of all three (Vav2-/- Vav3-/- Tiam1-/-), profoundly suppressing hyperproliferation, tumourigenesis and RAC1 activity, without impacting normal homeostasis. Critically, the observed RAC-GEF dependency was negated by oncogenic KRAS mutation. Together, these data demonstrate that while targeting RAC-GEF molecules may have therapeutic impact at early stages, this benefit may be lost in late stage disease., Funding: R.P.F was funded through a fellowship from the Royal Commission for the Exhibition of 1851. A.K.N. and L.B.Z. are funded through CRUK Grand Challenge Rosetta (A25045). S.K.F. is funded through the PCUK Future Leaders Academy (2017FutureLeadersAcademy). K.G. is funded through CRUK Grand Challenge Specificancer (A29055). L.M.M., M.B., K.I.A., M.D. and O.J.S. are supported through CRUK (A15673, A15565, A17096, A21139 and A17196 respectively). A.K.J. and M.T. are supported by BBSRC. D.M.G. and O.J.S. were also funded through ERC ColonCan (ERC starting grant 311301). Additionally, K.A.P., A.D.C., D.M.G., J.J., R.P.F., B.M., W.C., A.H., E.M., L.M.M., C.N., D.S., K.I.A., M.D. and O.J.S. are supported by CRUK Beatson core funding (A17196)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A RAC-GEF network critical for early intestinal tumourigenesis

  • Pickering, Karen
  • Unal, E. Besray
  • Kiel, Christina
  • Serrano Pubull, Luis, 1982-
  • Sansom, Owen J.
RAC1 activity is critical for intestinal homeostasis, and is required for hyperproliferation driven by loss of the tumour suppressor gene Apc in the murine intestine. To avoid the impact of direct targeting upon homeostasis, we reasoned that indirect targeting of RAC1 via RAC-GEFs might be effective. Transcriptional profiling of Apc deficient intestinal tissue identified Vav3 and Tiam1 as key targets. Deletion of these indicated that while TIAM1 deficiency could suppress Apc-driven hyperproliferation, it had no impact upon tumourigenesis, while VAV3 deficiency had no effect. Intriguingly, deletion of either gene resulted in upregulation of Vav2, with subsequent targeting of all three (Vav2-/- Vav3-/- Tiam1-/-), profoundly suppressing hyperproliferation, tumourigenesis and RAC1 activity, without impacting normal homeostasis. Critically, the observed RAC-GEF dependency was negated by oncogenic KRAS mutation. Together, these data demonstrate that while targeting RAC-GEF molecules may have therapeutic impact at early stages, this benefit may be lost in late stage disease., Funding: R.P.F was funded through a fellowship from the Royal Commission for the Exhibition of 1851. A.K.N. and L.B.Z. are funded through CRUK Grand Challenge Rosetta (A25045). S.K.F. is funded through the PCUK Future Leaders Academy (2017FutureLeadersAcademy). K.G. is funded through CRUK Grand Challenge Specificancer (A29055). L.M.M., M.B., K.I.A., M.D. and O.J.S. are supported through CRUK (A15673, A15565, A17096, A21139 and A17196 respectively). A.K.J. and M.T. are supported by BBSRC. D.M.G. and O.J.S. were also funded through ERC ColonCan (ERC starting grant 311301). Additionally, K.A.P., A.D.C., D.M.G., J.J., R.P.F., B.M., W.C., A.H., E.M., L.M.M., C.N., D.S., K.I.A., M.D. and O.J.S. are supported by CRUK Beatson core funding (A17196)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Extensive rewiring of the EGFR network in colorectal cancer cells expressing transforming levels of KRASG13D

  • Kennedy, Susan A.
  • Kiel, Christina
  • Serrano Pubull, Luis, 1982-
  • Kolch, Walter
Protein-protein-interaction networks (PPINs) organize fundamental biological processes, but how oncogenic mutations impact these interactions and their functions at a network-level scale is poorly understood. Here, we analyze how a common oncogenic KRAS mutation (KRASG13D) affects PPIN structure and function of the Epidermal Growth Factor Receptor (EGFR) network in colorectal cancer (CRC) cells. Mapping >6000 PPIs shows that this network is extensively rewired in cells expressing transforming levels of KRASG13D (mtKRAS). The factors driving PPIN rewiring are multifactorial including changes in protein expression and phosphorylation. Mathematical modelling also suggests that the binding dynamics of low and high affinity KRAS interactors contribute to rewiring. PPIN rewiring substantially alters the composition of protein complexes, signal flow, transcriptional regulation, and cellular phenotype. These changes are validated by targeted and global experimental analysis. Importantly, genetic alterations in the most extensively rewired PPIN nodes occur frequently in CRC and are prognostic of poor patient outcomes., This work was supported by European Union FP7 Grant No. 278568 “PRIMES” and Science Foundation Ireland Investigator Program Grant 14/IA/2395 to W.K. B.K. is supported by SmartNanoTox (Grant no. 686098), NanoCommons (Grant no. 731032), O.R. by MSCA-IF-2016 SAMNets (Grant no. 750688). D.M. is supported by Science Foundation Ireland Career Development award 15-CDA-3495. I.J. is supported by the Canada Research Chair Program (CRC #225404), Krembil Foundation, Ontario Research Fund (GL2-01-030 and #34876), Natural Sciences Research Council (NSERC #203475), Canada Foundation for Innovation (CFI #225404, #30865), and IBM. O.S. is supported by ERC investigator Award ColonCan 311301 and CRUK. I.S. is supported by the Canadian Cancer Society Research Institute (#703889), Genome Canada via Ontario Genomics (#9427 & #9428), Ontario Research fund (ORF/ DIG-501411 & RE08-009), Consortium Québécois sur la Découverte du Médicament (CQDM Quantum Leap) & Brain Canada (Quantum Leap), and CQDM Explore and OCE (#23929). T.C. was supported by a Teagasc Walsh Fellowship